Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Atomo Diagnostics Ltd. ( (AU:AT1) ) is now available.
Atomo Diagnostics has signed a long-term agreement with Newfoundland Diagnostics for the distribution of its HIV self-test kits, valued at approximately A$5.44 million over five years. This agreement strengthens Atomo’s market presence in the UK, EU, and Colombia, with exclusive distribution rights in the UK. Newfoundland has successfully launched Atomo’s products in major UK retail chains, facilitating market expansion. This partnership not only consolidates Atomo’s position in the global diagnostics market but also opens avenues for introducing new tests, such as the world’s first active syphilis self-test.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics is an Australian medical device company specializing in integrated rapid diagnostic test devices for the global market. Their patented devices enhance usability and reliability for both point-of-care and at-home testing applications. Atomo has commercialized products for infectious diseases such as HIV, syphilis, and early pregnancy detection in international markets.
YTD Price Performance: 5.26%
Average Trading Volume: 242,329
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$12.78M
See more data about AT1 stock on TipRanks’ Stock Analysis page.
